Y-ECI LCG and Y-ECI ROSC Webinar – Session 1

The first session of the joint Y-ECI LCG and Y-ECI ROSC Webinar series, dedicated to the latest advancements and discussions on brain metastases treatment, will be held on 11 October 2023, from 18:30-19:00 CET.

The topic of the first webinar is “Role of stereotactic intracranial radiotherapy in non-small cell lung cancer“, presented by Dr Arjun Sahgal and chaired by Dr Lizza Hendriks. The webinar will start with a 5-minute introduction, followed by a 15-minute presentation and a 10-minute discussion/Q&A.

Key topics to be covered:
1. Intracranial Radiosurgery vs. Whole Brain Radiotherapy (WBRT):
– When is it advisable to prescribe intracranial radiosurgery and when WBRT?
– What are the indications for stereotactic radiotherapy of multiple brain metastases?
2. Oncogene-Addicted NSCLC and Brain Metastases:
– At what stage is it recommended to prescribe intracranial local treatment?
– Should it be initiated upfront or after progression?
3. Systemic Therapy Interruption During Intracranial Radiotherapy:
– Is there a need to pause systemic therapy during intracranial radiotherapy?
– If so, what’s the recommended duration for the interruption?

About the speaker, Dr Arjun Sahgal:
Dr. Arjun Sahgal is an international clinical and research leader in the field of high precision stereotactic radiation to the brain and spine for both metastases and primary tumors. He currently serves as the Chief of the Department of Radiation Oncology at the University of Toronto affiliated Sunnybrook Odette Cancer Centre. In addition, he is the director of the Sunnybrook Cancer Ablation Therapy (CAT) program which involved the installation of a MR
Brachytherapy suite, MR Linac and Gamma Knife Icon technology. After training at the University of Toronto in radiation oncology, he completed a radiosurgery fellowship at the University of California San Francisco. He has published, as lead or as a contributor, over 500 peer reviewed papers including in high impact journals like the Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine.

Please use this MS Team link to attend the webinar.